ContraFect

ContraFect EBITDA per Share

The EBITDA per Share of ContraFect (CFRXQ) as of Oct 19, 2026 is -112.48 USD. In the previous year, EBITDA per Share was -102.76 USD — a change of 9.46% (lower).

EBITDA per Share

-112.48USD

YoY

9.46%

Last updated:

EBITDA per Share of ContraFect is 2022 -112.48 USD. EBITDA per Share of ContraFect was 2021 -102.76 USD. It decreases by 9.46% lower compared to the previous year.

The ContraFect EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2015
-835.67 USD
Jan 1, 2016
-838.25 USD
Jan 1, 2017
-379.43 USD
Jan 1, 2018
-311.20 USD
Jan 1, 2019
-278.70 USD
Jan 1, 2020
-122.29 USD
Jan 1, 2021
-102.76 USD
Jan 1, 2022
-112.48 USD
The ContraFect EBITDA per Share history
YEAREBITDA per ShareYoY
-112.48USD+9.46%
-102.76USD-15.97%
-122.29USD-56.12%
-278.70USD-10.44%
-311.20USD-17.98%
-379.43USD-54.74%
-838.25USD+0.31%
-835.67USD-50.67%
-1,694.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

EBITDA per Share of ContraFect is -112.48 USD in 2022.

EBITDA per Share of ContraFect changed from -102.76 USD to -112.48 USD, representing a 9.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share ContraFect since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ContraFect

All Key Metrics — ContraFect